VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XERSXeris Biopharma Holdings, Inc.
$16.80$2.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
XERS logo

Xeris Biopharma Holdings, Inc.

XERS
NASDAQ · Rare Disease Biotech
$16.80
At close - Nov 17, 4:00 PM EST - USD
Market Cap$2.9B
P/E-491.2x
52W High$16.98
Volume2.66M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Revenue Acceleration Offsets Leverage and Equity Risks

Xeris Biopharma is executing a sharp revenue acceleration, with 28.7% YoY growth in 2026Q2 and gross margins expanding to 86.4%, signaling strong commercial traction and pricing power.

GrowthAccelerating
ProfitabilityStable
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

XERS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-1912% Peers

P/E is 1912% below peer median

03

Market leadership

RS 98 · Leader

High momentum (Outperforming 98% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
XERS+128.57%
S&P 500 (^GSPC)+7.21%
1-Year Return
XERS+131.41%
S&P 500 (^GSPC)+10.03%
3-Year Return
XERS+849.15%
S&P 500 (^GSPC)+30.81%
5-Year Return
XERS+585.71%
S&P 500 (^GSPC)+52.53%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-496.8x
Forward P/E
3398.0x
EV/EBITDA100th %ile
48.2x
FCF YieldCash Flow
2.5%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-496.8x
N/A
N/A
EV/EBITDA
48.2x
34.6x
100th· High
Price/FCF
40.4x
48.6x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$4.91-70.8%
Base (Fair)$8.53-48.8%
Bull$10.06-40.1%
$4.91 Bear$8.53 Base$10.06 Bull
Current Market Price: $16.80
Trades at a 97.0% premium to Base DCF ($8.53)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$292M+43.7% YoY
Net income FY25
$554K+101.0% YoY
Free cash flow FY25
$28M+173.8% YoY
Operating margin FY25
8.5%+25.1 pts YoY
ROIC (FY25)33.8%
Avg ROIC 5Y-28.8%
ROE (TTM)-39.5%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.06+89.5%
vs $0.03
$107M+5.5%
vs $102M
Q3 2026
Aug 6, 2026
-$0.18-1582.7%
vs $0.01
$91M+1.0%
vs $90M
Q2 2026
May 7, 2026
$0.01+465.0%
vs -$0.00
$82M+3.3%
vs $80M
Q2 2026
Mar 2, 2026
$0.06+100.0%
vs $0.03
$86M+4.4%
vs $82M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Fool - Investing News·3d ago
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?

Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.

Seeking Alpha·6d ago
Xeris Biopharma: Time For A Pause

Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth to $107.2M, exceeding expectations. Gross margins improved to 88%, and Xeris eliminated $34M of convertible notes, reducing annual interest by $3M and strengthening its balance sheet.

Fool - Investing News·Nov 11, 2026
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?

One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.

MarketBeat·Nov 6, 2026
Xeris Biopharma Q3 Earnings Call Highlights

Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.

Filtered for Xeris Biopharma Holdings, Inc.More Headlines
04

Compare before deciding

Benchmark XERS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Xeris Biopharma Holdings, Inc. (XERS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
XERS logoXERSXeris Biopharma Holdings, Inc.Current
$16.80$2.9B-491.2343.72%-1.76%-39.52%—
LNTH logoLNTHLantheus Holdings, Inc.
$101.80$6.63B25.800.5%17.28%21.72%—
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$29.04$3.54B7.874.29%32.75%——
PAHC logoPAHCPhibro Animal Health Corporation
$34.92$1.42B13.9217.12%6.67%27.44%1.36%
CORT logoCORTCorcept Therapeutics Incorporated
$70.07$7.52B53.2912.79%16.81%22.94%—
AMRX logoAMRXAmneal Pharmaceuticals, Inc.
$21.12$6.74B48.058.05%4.62%82.23%—

Compare XERS vs Peers

Xeris Biopharma Holdings, Inc. (XERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LNTH

Most directly comparable listed peer for XERS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare XERS against a more recognizable public peer.

Peer Set

Compare Top 5

vs LNTH, SUPN, PAHC, CORT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

XERS SEC Filings & Documents

Xeris Biopharma Holdings, Inc. (XERS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jul 17, 2026·SEC

Material company update

Jun 30, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 6, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when XERS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

XERS Frequently Asked Questions

Xeris Biopharma Holdings, Inc. (XERS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Xeris Biopharma Holdings, Inc.'s revenue?

Xeris Biopharma Holdings, Inc. (XERS) reported $368.3M in revenue over the trailing twelve months. Revenue was $291.8M in fiscal year 2025. That is 27048% more than the $1.1M of fiscal year 2016.

How fast is Xeris Biopharma Holdings, Inc. growing?

Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 38.4% over the trailing twelve months, compared with the twelve months before.

Is XERS profitable?

No. Xeris Biopharma Holdings, Inc. (XERS) reported a net loss of $6.5M over the trailing twelve months.

Dividend & Returns
What is XERS's return on equity?

Xeris Biopharma Holdings, Inc. (XERS) had a return on equity (ROE) of -39.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Xeris Biopharma Holdings, Inc.'s free cash flow?

Xeris Biopharma Holdings, Inc. (XERS) generated $72.6M in free cash flow over the trailing twelve months.

What if you invested $1,000 in XERS back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →